Cart
sales@molnova.com
Home - Products - Cell Cycle/DNA Damage - Integrin - ILK-IN-3

ILK-IN-3

CAS No. 6975-75-3

ILK-IN-3( —— )

Catalog No. M22072 CAS No. 6975-75-3

ILK-IN-3 is an inhibitor of integrin linked kinase, and with antitumor activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 164 In Stock
10MG 262 In Stock
25MG 471 In Stock
50MG 683 In Stock
100MG 954 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    ILK-IN-3
  • Note
    Research use only, not for human use.
  • Brief Description
    ILK-IN-3 is an inhibitor of integrin linked kinase, and with antitumor activity.
  • Description
    ILK-IN-3 is an inhibitor of integrin linked kinase, and with antitumor activity.(In Vitro):ILK-IN-3 (compound 4, 10 μM) inhibits DYRK1, GSK3α/β, CDK5/p25 kinase activity to 17%, 51%, 47%, 95%, respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Integrin
  • Recptor
    Integrin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    6975-75-3
  • Formula Weight
    232.24
  • Molecular Formula
    C10H12N6O?
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 83.33 mg/mL (358.81 mM)
  • SMILES
    COC1=CC=C(C=C1)N=NC2=C(NN=C2N)N
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Jessica Kalra, et al. Validating the Use of a Luciferase Labeled Breast Cancer Cell Line, MDA435LCC6, as a Means to Monitor Tumor Progression and to Assess the Therapeutic Activity of an Established Anticancer Drug, Docetaxel (Dt) Alone or in Combination With the ILK Inhibitor, QLT0267. Cancer Biol Ther. 2011 May 1;11(9):826-38.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • LXW7

    LXW7 is an octamer disulfide cyclic peptide and αvβ3 integrin ligand, acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand. LXW7 is a disulfide cyclic octa-peptide (cGRGDdvc) containing unnatural amino acids flanking both sides of the main functional motif.

  • Tadocizumab

    Tadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin αIIbβ3 with antiplatelet and antithrombotic activity that blocks the platelet αIIbβ3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease.

  • Cyclo(RADfK)

    Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.Cyclo(RADfK) is a negative control for the cyclo (-RGDfK-), the RGD peptide.

Sign In Join Free